GSK's Vaccines Chief Slaoui To Follow Witty Out The Door

One person definitely not lining up to take over from Sir Andrew Witty when he retires from GlaxoSmithKline PLC in March 2017 is its vaccines chief and former head of R&D Dr. Moncef Slaoui. He is to retire from the company in June 2017.

Moncef Slaoui
Moncef Slaoui • Source: GSK

Slaoui spearheaded the overhaul of GlaxoSmithKline PLC pharmaceutical R&D and was instrumental in its DPU (discovery performance unit) initiative. Like Andrew Witty, Moncef Slaoui has spent the bulk of his career at GSK in a variety of roles spanning 28 years. (Also see " Witty Succumbs To Pressure: GSK Starts Formal Search For New CEO " - Scrip, 18 March, 2016.)

Prior to his current role as chairman of vaccines, where he oversaw the integration with the Novartis AG vaccines...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip